Fig. 5

A. MDA-MB-231 oxygen consumption rates (OCR (pmol/min)) vs. time after injection of (i) treatment or DMSO (ii) oligomycin (iii) FCCP and (iv) Rotenone and Antimycin A after treatment with B/N (1-0.0625 µM). B. MDA-MB-231 extracellular acidification rates (ECAR (mpH/min)) vs. time after injection of (i) treatment or DMSO (ii) oligomycin (iii) FCCP and (iv) Rotenone and Antimycin A after treatment with B/N (1-0.0625 µM). C. ΔOCR subtracting non-mitochondrial respiration from OCR after oligomycin of DMSO control and after acute B/N injection (1-0.0625 µM) indicating proton leak in MDA-MB-231 cells. D. Maximal respiration OCR of DMSO control and after treatment with B/N (1-0.0625 µM) in MDA-MB-231 cells. E. Spare respiratory capacity OCR from subtracting OCR before oligomycin injection from maximal respiration in MDA-MB-231 cells. F. 4T1 oxygen consumption rates (OCR (pmol/min)) vs. time after injection of (i) treatment or DMSO (ii) oligomycin (iii) FCCP and (iv) Rotenone and Antimycin A after treatment with B/N (1-0.0625 µM). G. 4T1 extracellular acidification rates (ECAR (mpH/min)) vs. time after injection of (i) treatment or DMSO (ii) oligomycin (iii) FCCP and (iv) Rotenone and Antimycin A after treatment with B/N (1-0.0625 µM). H. ΔOCR subtracting non-mitochondrial respiration from OCR after oligomycin of DMSO control and after acute B/N injection (1-0.0625 µM) indicating proton leak in 4T1 cells. I. Maximal respiration OCR of DMSO control and after treatment with B/N (1-0.0625 µM) in 4T1 cells. J. Spare respiratory capacity OCR from subtracting OCR before oligomycin injection from maximal respiration in 4T1 cells. C,D,E,H,I,J: results are representative of 3 biological replicates experiments having a combined total of 15 technical replicates per group ± SEM. Statistical analysis was carried out via Dunnett’s one-way ANOVA compared to DMSO control (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001)